Open AccessMulticenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study
Author(s) -
An S. De Vriese,
Rogier Caluwé,
Lotte Pyfferoen,
Dirk De Bacquer,
K. De Boeck,
Joost Delanote,
Didier De Surgeloose,
Piet Van Hoenacker,
Bruno Van Vlem,
Francis Verbeke
Publication year - 2019
Publication title -
journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.451
H-Index - 279
eISSN - 1533-3450
pISSN - 1046-6673
DOI - 10.1681/asn.2019060579
Subject(s) - medicine , rivaroxaban , atrial fibrillation , vitamin k2 , vitamin k antagonist , hemodialysis , cardiology , randomized controlled trial , stroke (engine) , vitamin , warfarin , mechanical engineering , engineering
Vitamin K antagonists (VKAs), although commonly used to reduce thromboembolic risk in atrial fibrillation, have been incriminated as probable cause of accelerated vascular calcification (VC) in patients on hemodialysis. Functional vitamin K deficiency may further contribute to their susceptibility for VC. We investigated the effect of vitamin K status on VC progression in 132 patients on hemodialysis with atrial fibrillation treated with VKAs or qualifying for anticoagulation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom